AstraZeneca Plc has reported trial data for a new combination therapy directed against muscle-invasive bladder cancer which showed improvements in event-free survival for the patients concerned. The muscle-invasive disease is estimated to affect one in four people with bladder cancer and arises when a tumour invades the bladder’s muscle wall. The standard treatment for these patients is surgery, with or without an adjuvant treatment.
Marty Makary, the British-American surgeon and public health researcher, has resigned as commissioner of the US Food and Drug Administration after serving in the post for just over a year. He will be replaced, on an interim basis, by Kyle Diamantas, the agency’s deputy commissioner for food. The resignation was reported by Politico on 12 May and later confirmed by President Donald Trump to reporters the same day ahead of his trip to China.
Bristol Myers Squibb Co announced a drug discovery and development agreement with Jiangsu Hengrui Pharmaceuticals Co Ltd on 12 May which is expected to yield 13 new products across the oncology, haematology, and immunology sectors and be commercialised across the globe. The deal comes as Hengrui is expanding its market presence outside China and BMS is taking steps to generate new revenue in response to a loss of patent protection on some important medicines.
Preparing for the next pandemic
The role of real-world data in medical care
Venture debt as an option for start-up companies
Kailera taps IPO market for obesity
Gilead to acquire Tubulis
Q1 resilient with signs of recovery continuing
Early warnings for Parkinson's disease
